A5092007468- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
University of North Carolina at Chapel Hill
2023-2024
The CDK4/6 inhibitor palbociclib blocks cell cycle progression in Estrogen receptor-positive, human epidermal growth factor 2 receptor-negative (ER+/HER2-) breast tumor cells. Despite the drug's success improving patient outcomes, a small percentage of cells continues to divide presence palbociclib-a phenomenon we refer as fractional resistance. It is critical understand cellular mechanisms underlying resistance because precise resistant tissue strong predictor clinical outcomes. Here,...
ABSTRACT The CDK4/6 inhibitor palbociclib blocks cell cycle progression in ER+/HER2- breast tumor cells. Although these drugs have significantly improved patient outcomes metastatic cancers, a small percentage of cells continues to divide the presence palbociclib—a phenomenon we refer as fractional resistance. It is critical understand cellular mechanisms underlying resistance because precise resistant tissue strong predictor clinical outcome. Here, hypothesize that arises from cell-to-cell...